HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Bio-Thera Solutions Ltd / Equity Capital Markets

In February 2020, <a href="https://www.smartkarma.com/entities/bio-thera-solutions-ltd" target="_blank" data-smartkarma-citation="entities:29127:1" rel="noopener">Bio-Thera Solutions Ltd (688177 CH)</a> completed its listing on the SSE STAR Market. Then in 2020/2H, Bio-Thera planned to list on the Hong Kong Stock Exchange, becoming another biopharmaceutical company with "A+H" listing. Currently the Company’s market value was about RMB13.5 billion. So how about this company? The following provides the insights on its pipeline and related competitive landscape.

In February 2020, Bio-Thera Solutions Ltd (688177 CH) completed its listing on the SSE STAR Market. Then in 2020/2H, Bio-Thera planned to list on the Hong Kong Stock Exchange, becoming another biopharmaceutical company with "A+H" listing. Currently the Company’s market value was about RMB13.5 billion. So how about this company? The following provides the insights on its pipeline and related competitive landscape. 

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

Thematic (Sector/Industry)

On December 28th 2020, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. The new medical insurance catalogue will be officially implemented on March 1st, 2021. It totally contains 2,800 types of drugs, including 1,426 types of western medicine and 1,374 types of proprietary Chinese medicine. A total of 162 drugs were negotiated this time, 119 of which successfully won the bidding, with a success rate of 73.46% and an average price reduction of 50.64%. The list of the 119 drugs is on the final page.

On December 28th 2020, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. The new medical insurance catalogue will be officially implemented on March 1st, 2021. It totally contains 2,800 types of drugs, including 1,426 types of western medicine and 1,374 types of proprietary Chinese medicine. A total of 162 drugs were negotiated this time, 119 of which successfully won the bidding, with a success rate of 73.46% and an average price reduction of 50.64%. The list of the 119 drugs is on the final page.

China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations

1. Industry viewpoints:<ul>
<li>Last week, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. </li>
<li>The negotiations results showed that all three domestic PD-1/L1 had successfully won the bidding to be included in the medical insurance.</li>
<li>Transdermal drug delivery systems (TDDS) is a hot research direction of improved new drugs, among which cataplasm has great development potential.</li>
</ul>2. Company news: News about the progress of new drugs and results of 2020 medical insurance negotiations from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a> and <a href="https://www.smartkarma.com/entities/hutchison-china-meditech-ltd-7c2c4b58-ca71-4ac4-befb-345e8d0f10ca" target="_blank" data-smartkarma-citation="entities:27342:1" rel="noopener">Hutchison China MediTech Ltd (HCM US).</a>3. Market review:Last week, stock price for healthcare sector in A share increased 0.33%, while CSI 300 increased 3.36% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
Last week, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. 
The negotiations results showed that all three domestic PD-1/L1 had successfully won the bidding to be included in the medical insurance.
Transdermal drug delivery systems (TDDS) is a hot research direction of improved new drugs, among which cataplasm has great development potential.
2. Company news: News about the progress of new drugs and results of 2020 medical insurance negotiations from Innovent Biologics Inc (1801 HK), Jiangsu Hengrui Medicine (600276 CH) and Hutchison China MediTech Ltd (HCM US).3. Market review:Last week, stock price for healthcare sector in A share increased 0.33%, while CSI 300 increased 3.36% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

New Horizon Health  / Equity Capital Markets

New Horizon Health is a China-based cancer diagnostics company that has filed an Application Proof to list on the HKEX. The company has innovative screening technologies for colorectal, gastric, and potentially cervical cancer. The management team is accomplished and the pre-IPO investors are experienced healthcare funds. We view the company favorably and will provide a definitive view in a future Insight closer to the actual offering.

New Horizon Health is a China-based cancer diagnostics company that has filed an Application Proof to list on the HKEX. The company has innovative screening technologies for colorectal, gastric, and potentially cervical cancer. The management team is accomplished and the pre-IPO investors are experienced healthcare funds. We view the company favorably and will provide a definitive view in a future Insight closer to the actual offering.

First of all, Merry Christmas and Happy New Year!
1. Industry viewpoints:
<ul>
<li>While we are still waiting for the official results of the volume-based purchase (VBP) negotiations in 2020, let’s take a further look at the competitive landscape of PD-1/L1 in China.</li>
<li>The regenerative medical implant devices would be a development trend of medical implant devices in the future.</li>
<li>Affected by the centralized procurement policy in China, the growth rate of high-value medical consumables market is expected to slow year by year.</li>
</ul>
2. Company news:
News about the progress of new drugs from <a href="https://www.smartkarma.com/entities/alphamab-oncology" target="_blank" data-smartkarma-citation="entities:28213:1" rel="noopener">Alphamab Co Ltd (9966 HK)</a>, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, <a href="https://www.smartkarma.com/entities/ascletis-pharma-inc" target="_blank" data-smartkarma-citation="entities:27265:1" rel="noopener">Ascletis Pharma Inc (1672 HK)</a> and <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>.
3. Market review:
Last week, stock price for healthcare sector in A share increased 1.1%, while CSI 300 increased 0.84% over the same period of time.
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

First of all, Merry Christmas and Happy New Year!
1. Industry viewpoints:

While we are still waiting for the official results of the volume-based purchase (VBP) negotiations in 2020, let’s take a further look at the competitive landscape of PD-1/L1 in China.
The regenerative medical implant devices would be a development trend of medical implant devices in the future.
Affected by the centralized procurement policy in China, the growth rate of high-value medical consumables market is expected to slow year by year.

2. Company news:
News about the progress of new drugs from Alphamab Co Ltd (9966 HK), Innovent Biologics Inc (1801 HK), Ascletis Pharma Inc (1672 HK) and Jiangsu Hengrui Medicine (600276 CH).
3. Market review:
Last week, stock price for healthcare sector in A share increased 1.1%, while CSI 300 increased 0.84% over the same period of time.
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (6160 HK)

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...

Xinyao (Criss) Wang

China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations

The article analyzed the results of 2020 medical insurance negotiations with the list of drugs that won the bidding. If interested in China...

Xinyao (Criss) Wang

China Healthcare Weekly (Dec.31)

This article summarized the industry viewpoints including the results of China 2020 medical insurance negotiations, TDDS, companies news of...

Xinyao (Criss) Wang

New Horizon IPO: Leaning Positive

New Horizon Health is a cancer diagnostics company that plans to list on the HKEX. The company has innovative tests for CRC, gastric, and...

Kemp Dolliver, CFA

China Healthcare Weekly (Dec.25)

This article analyzed healthcare industry viewpoints such as competitive landscape of PD-1/L1 in China, news of Alphamab, Hengrui, Innovent and...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)